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Executive Summary 
 
 
This study will examine differences in pharmaceutical utilization rates relative to 
financial risk arrangements of differing insurance plans.  During the last four years we have 
noted consistent differences in utilization of expensive, psychotropic medications between 
individuals enrolled in Health Maintenance Organizations (HMOs), which are at financial risk 
for the provision of pharmaceuticals, and the MediPass program in which the state bears the risk 
of pharmacy expenses.  Persons in HMOs had lower levels of utilization.  
In this study we expand these analyses to include a broader range of pharmaceutical 
agents than were considered earlier and a broader range of diagnostic groups including the 
addition of children. To complete these analyses we defined diagnostically homogeneous groups 
using claims data from the community mental health and targeted case management services.  
We calculated the annual prevalence of nine mental health diagnoses, which was defined as the 
proportion of the Medicaid population that received only one primary diagnosis (e.g., 
schizophrenia) during the study year.  Individuals with multiple primary diagnoses within the 
severe mental illnesses (SMI) range were grouped into a “multiple severe mental illness” group.   
We then calculated the utilization rate of several classes of psychotropic medications.   
Penetration rate was defined as the number of people within a specific diagnosis group 
who had at least one filled prescription for a defined pharmaceutical class within the study period 
divided by the total number of persons in the diagnostic group.  Standard cost rates were 
calculated by multiplying the statewide MediPass claim average for the NDC code of each filled 
prescription by the filled prescriptions in a diagnostic sub-group divided by the number of 
member months of individuals in the total diagnostic sub-group. 
Results indicated that prevalence of severe mental illnesses, access to and utilization of 
more expensive pharmaceuticals was related to insurance plan.  As with the pre-paid mental 
health plan evaluation, those persons who were enrolled in plans at risk for pharmacy costs (i.e., 
HMOs) had a lower rate of utilization of expensive drugs.  Also, persons with more severe 
disorders were less prevalent in the HMO plans.  Standard costs and utilization, for those who 
were given access, were lower in HMO financing plans relative to the MediPass plan for persons 
in the Adult Schizophrenia group who were taking atypical anti-psychotic (AAP) medication.  
This was not the case for other diagnostic groups and pharmaceutical categories. Several 
questions are raised by these findings.  Given a diagnosis, why is access to pharmaceuticals so 
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much lower in the HMO financing condition?  Differences in utilization rates of more expensive 
pharmaceuticals clearly need further investigation. 
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Background 
 
 For the past four years, we have contrasted drug use patterns between two insurance 
plans that differ in their risk for pharmacy expenses.  These analyses were included as part of a 
more extensive evaluation of Florida’s Prepaid Mental Health Plan in AHCA Area 6, the Tampa 
Bay region.  Specifically, the annual penetration of filled prescriptions for atypical anti-psychotic 
agents for people with a diagnosis of schizophrenia and the annual penetration of filled 
prescriptions for SSRI Anti-depressants for people with a diagnosis of Major Depression was 
compared across financing conditions.    
We have consistently reported that people with a diagnosis of schizophrenia have a much 
lower penetration of filled prescriptions for atypical agents in the HMO condition compared to 
the PMHP condition, and that people with a diagnosis of major depression have a slightly lower 
penetration rate for filled SSRI Anti-depressants prescriptions in the HMO condition as 
compared to the PMHP condition. (Shern, Giard, Robinson, Stiles, Boothroyd, Murrin, Chen, 
Moss, Dailey, Thornton, & Armstrong, 2002; Shern, Giard, Robinson, Stiles, Boothroyd, Murrin, 
Chen, Boaz, Dow & Ward, 2001; Shern, Robinson, Stiles, Boothroyd, Giard, & Murrin, 2000; 
Shern, Robinson, Boothroyd, Stiles, Snyder, Murrin, Armstrong, Kershaw, Lee, Massey, Dow, 
Ward, & Boaz, 1999).   We have interpreted these differences in penetration rates to be a 
function of the differential risk arrangements that characterize the two conditions.  HMOs are at 
risk for the expense of pharmaceuticals while the PMHP is not at risk for these expenses. 
In the 2002 evaluation report (Shern et al., 2002) the annual penetration of these two 
classes of drugs for their primary target populations was examined over the entire six years of the 
evaluation.  We found that penetration of SSRI Anti-depressants for persons with major 
depression was consistently higher in the PMHP condition than in the HMO condition while the 
differences between the conditions became attenuated over time as the HMO rates approached 
those of the PMHP.  The penetration rate of atypical agents for persons with schizophrenia has 
steadily increased in all conditions over the six-year period, with the penetration of atypicals for 
people with schizophrenia being about 10-15% lower in the HMO condition than in the PMHP.    
As we noted earlier, financial risk for pharmaceutical expenses appears to be associated with 
lower access to newer, more expensive pharmaceuticals (Shern et al., 2002).  However, our 
observations have been restricted to two AHCA Areas (4 and 6) and we know little about the 
  4
area-to-area variation in penetration of psychotropic agents and how penetration might be related 
to the financial risk arrangements across areas.   
In this study we will address these issues by expanding the scope of the analyses 
conducted in the PMHP evaluation in several ways.  First, we included data from throughout the 
state. Second, we identified an expanded range of diagnostically homogeneous populations.  
Third, we added children to our analyses focusing on three major diagnostic groups: Childhood 
Depression, Childhood ADHD, and Childhood Disruptive Behavior.  Fourth, we replicated our 
procedures for calculating the annual penetration rate for the use of an expanded group of 
pharmaceuticals that are commonly used for individuals in each of the diagnostic groups.  
Finally, we contrasted these penetration rates between persons who are enrolled in HMOs and 
individuals enrolled in the MediPass program.  Based on this framework, we have defined the 
following research questions.  
 
1) What is the proportion of Florida Medicaid’s adult population who has schizophrenia, 
major depression, bipolar disorder, other SMI disorders, or combination-SMI disorders 
(diagnoses in more than one group) in the study year? How does these rates vary by area 
and financing condition? 
2) What is the proportion of Florida Medicaid’s child/adolescent population who has a 
diagnosis of childhood depression, childhood ADHD, childhood disruptive behavior 
disorders, and other SMI conditions?  How does this vary by area and financing 
condition? 
3) What is the proportion of adults with Schizophrenia who have a filled prescription for an   
atypical antipsychotic agent?    How does this drug penetration rate vary by area and 
financing condition? 
4) What is the proportion of adults with Major Depression who have filled a prescription for 
an SSRI Anti-depressant or a Newer Antidepressant agent? How does this drug 
penetration rate vary by area and financing condition? 
5) What is the penetration (percent of the people in the group with at least one filled 
prescription) of SSRI Anti-depressants and Newer Antidepressant agents for children 
with Child/Adolescent Major Depression?  How does this vary by area and financing 
condition? 
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6) What is the percent of the children with a diagnosis of Child/Adolescent ADHD who 
have a filled prescription for an anti-hyperkinesis agent? How does this drug penetration 
rate vary by area and financing condition? 
7) What are the utilization rates of various other psychotropic drug classes for persons in the 
differing diagnostic groups?  
8) What is the penetration of preferred and commonly used drugs on the AHCA Preferred 
Drug List formulary for each diagnostic group?  How does this vary among HMO 
providers? 
   
Methods and Population Characteristics for Overall Analysis 
 
Data Sets. The datasets included in this study are outlined in Table 1. 
 
Table 1: Data Sets Required 
Data sets to be employed in the analysis 
Data set name and dates ranges Use 
AHCA Statewide Eligibility File 
July 2000-June 2001 
(March 2000-February 2001 Area 6) 
To determine the total population within 
each eligibility group. 
AHCA Statewide Fee-for-Service Claims 
File 
July 2000-June 2001 
(March 2000-February 2001 Area 6) 
Medical claims to determine diagnosis 
groups; 
Capitation payments to determine the 
HMO provider for each Medicaid 
Recipient and to confirm PMHP 
membership in Area 6; 
Pharmacy Claims to determine the Mental 
Health Pharmaceuticals used and the 
utilization rate in the MediPass Condition. 
AHCA HMO Statewide Drug Claims File 
July 2000-June 2001 
(See appendix 1 for limitations of this data) 
Pharmacy Claims to determine the Mental 
Health Pharmaceuticals used and the 
utilization rate in the HMO Condition. 
Managed Care Area 6 Claims file 
March 2000 – February 2001 
Medical (HMO) and Mental Health 
(HMO/PMHP) provider claims to 
determine diagnosis groups for PMHP and 
HMO conditions. 
HMO Area 6 Pharmacy file 
March2000 - June 2000 
Pharmacy Claims to determine the Mental 
Health Pharmaceuticals used and the 
utilization rate in the HMO Condition. 
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Subject Selection.  Subjects were selected from all Florida Medicaid recipients with the 
following characteristics: ages from 1-64, in either the MediPass or HMO financing plans 
(confirmed by capitation payments (MediPass=W9893, PMHP (Area 6 only)=W1078, 
HMO=W9600 for each month while enrolled in condition), and in the AFDC, SSI Non- 
Medicare, Foster Care (under age 21), and SOBRA (under age 21) eligibility groups.   Date 
ranges for eligibility in Area 6 were from March 1, 2000-February 28, 2001, which corresponds 
to the FY for the PMHP Evaluation.  As all mental health services are provided under managed 
care in Area 6, complete outpatient service records could only be established for this period.  
Date ranges for eligibility for the remainder of the state were from July 1, 2000 until June 30, 
2001.  HMO pharmacy data were only available for this period.  Eligible months for HMOs that 
were missing pharmacy data were removed from the analysis.  Characteristics of individual 
meeting the above criteria are summarized in Table 2. 
As may be seen from the Table, a total of approximately 1.1 million children and 379,000 
adults met the selection criteria.  The differences in the characteristics of HMO and MediPass 
enrollees were fairly consistent across areas with the HMO enrollees being less likely to be on 
SSI or in Foster Care, more likely to be female, and more likely to be African-American.  There 
was a slightly higher percentage in the 55-64 age group in the MediPass condition relative to the 
HMO condition.  For children, age distributions were relatively equivalent. 
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Table 2: Statewide Demographic Characteristics of Total Eligible Study Population by Age 
Group and Financing Plan1  
 Percent of Financing Plan 
 HMO MP 
Percent in SSI or FC: 
      Children (SSI and FC) 
      Adults (SSI only) 
  8.01% of 498,004
33.73% of 165,106
14.11% of 616,651
46.71% of 214,098
Percent Female: 
      Children 
      Adults 
50.35% of 498,004
76.83% of 165,106
49.13% of 616,651
70.95% of 214,098
Percent Minority: 
African- American 
      Children 
      Adults 
 
   46.31% of 498,004
40.68% of 165,106
 
   31.64% of 616,651
28.17% of 214,098
Other Minority 
     Children 
      Adults 
 
   26.94% of 498,004
   23.90% of 165,106
 
   32.14% of 616,651
28.76% of 214,098
Percent Age Distribution with Age Group
      Ages 1-5 
      Ages 6-13  
      Ages 14-20 
      Ages 21-54 
      Ages 55-64 
40.64% of 498,004
42.49% of 498,004
19.40% of 498,004
91.85% of 165,106
8.27% of 165,106
42.14% of 616,651
40.60% of 616,651
19.14% of 616,651
86.77% of 214,098
13.35% of 214,098
 
 Assignment to Diagnostic Groups.   Individual mental health claims for Community 
Mental Health (CMH) and Targeted Case Management (TCM) service programs for the 1.5 
million individuals identified statewide were categorized as follows (see Table 3).  All claims for 
a specific individual were aggregated.  Each claim was examined to identify the primary 
diagnosis.  Including individuals who did not receive a diagnosis from more than one group 
formed the homogeneous diagnostic groups.  For example, persons placed in the Adult 
Schizophrenia group had at least one claim in which their primary diagnosis was schizophrenia 
and had no claims with a primary diagnosis of major depression or bi-polar disorder.   Adults 
with diagnoses in more than one group were assigned to “Adult Multiple Serious Mental 
Illnesses (SMI) ”.  Children in more than one group were assigned to “Child/Adolescent Multiple 
SMI ”.  All individuals who were classified into one of these groups comprised the population 
with severe mental illnesses.
                                                 
1 People switching categories over the course of the year for age or eligibility plans will be represented more than 
once. 
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Table 3: Diagnostic Category Definitions 
Age Criteria Diagnostic Criteria The Diagnostic Label is: 
Age >= 21  Primary Diagnosis 295- 295.39 and 
295.9 (simple, disorganized, catatonic, 
paranoid, unspecified) 
Adult Schizophrenia 
 
Age >= 21 Primary Diagnosis 296.2 through 296.39 
(major depression single or recurrent 
episode) 
Adult Depression 
Age >= 21  Primary diagnosis 296.0-296.19 (manic 
disorder) or primary diagnosis (296.4-
296.89) which includes all the bipolar 
disorders and the manic-depressive 
psychoses 
Adult Bipolar 
Age >=21 Primary diagnosis 295-296.99 not in 
above 3 classes (latent, residual, schizo-
affective, other schizophrenia, and 
unspecified affective disorder) 
Adult Other SMI 
Age < 21 Primary diagnosis from 296-296.39 
(major depression), not excluding those 
with concomitant Child/Adolescent 
Adjustment reaction diagnoses 
Child/Adolescent Major 
Depression 
Age < 21 Primary diagnosis between 309-309.9 
excluding 309.21 and 309.81 
(adjustment reactions except for 
separation anxiety and prolonged post-
traumatic stress disorder) 
Child/Adolescent 
Adjustment Reactions 
Age < 21 Primary diagnosis of 312.8 (Specified 
disturbances of conduct), 312.81 
(Childhood onset conduct disorder), 
312.82 (Adolescent onset conduct 
disorder), and 312.9 (Unspecified 
disturbance of conduct) 
Child/Adolescent Conduct 
Disorder 
Age < 21 Primary diagnosis 314-314.99 (hyper 
kinetic syndromes of childhood) 
Child/Adolescent ADHD 
Age <21 Other diagnoses in the range of 295-
296-99, 311-312.99, 314-314.99 
Child/Adolescent Other 
SMI 
 
The demographic characteristics of the sub-populations with SMI are shown in Table 3. 
Not surprisingly, the percentage of SSI/FC children is more than four times higher in the sub-
group of children/adolescents than in the overall population of Medicaid enrollees.  Similarly, 
the percentage of SSI adults is more than three times that of the general Medicaid population.   
The child population with SMI is more predominately male than the general population while 
individuals from minority groups are slightly under-represented in the SMI sub-population.  In 
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the HMO condition, the percentage of individuals enrolled in the SSI/FC group is lower than in 
the MP condition, but the percentage of minorities is greater in the HMO condition. 
 
Table 4: Statewide Demographic Characteristics of SMI sub-population by Age Group and 
Financing Plan2
 Percent of Financing Plan 
 HMO MP 
Percent in SSI or FC: 
      Children (SSI and FC) 
      Adults (SSI only) 
 
36.12% of 16,049
80.19% of   7,637
 
50.43% of 33,002 
87.31% of 25,011 
Percent Female: 
      Children 
      Adults 
 
35.15% of 16,049
72.17% of   7,637
 
35.07% of 33,002 
66.90% of 25,011 
Percent Minority: 
African- American 
      Children 
      Adults 
 
41.55% of 16,049
28.39% of   7,637
 
27.08% of 33,002 
18.03% of 25,011 
Other Minority 
     Children 
      Adults 
 
25.09% of 16,049
28.26% of   7,637
 
27.62% of 33,002 
37.60% of 25,011 
  
14.18% of 16,049 13.25% of 33,002 
69.80% of 16,049 65.53% of 33,002 
20.14% of 16,049 24.03% of 33,002 
90.00% of   7,637 80.99% of 25,011 
Percent Age Distribution within Age Group
      Ages 1-5 
      Ages 6-13  
      Ages 14-20 
      Ages 21-54 
      Ages 55-64 10.31% of   7,637 19.40% of 25,011 
The statewide prevalence within each diagnostic group, as defined by the primary diagnosis 
recorded in the Community Mental Health or Targeted Case Management data sets is displayed 
in Table 4.  From this table it is clear that prevalence of SMI classification is consistently higher 
statewide in the MP financing condition than in the HMO condition for most diagnostic sub-
groups.  This is particularly the case for adults. 
                                                 
2 People switching categories over the course of the year for age or eligibility plans will be represented more than 
once. 
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Table 5: Statewide Annual Prevalence of Selected Diagnoses as Reflected in Primary 
Diagnosis recorded in Community Mental Health or Targeted Case Management Data Sets  
 Percent of Financing Plan 
Adults HMO (N=165,106) MP (N=214,098)
Adult Schizophrenia 0.95% 2.48% 
Adult Major Depression 1.92% 4.64% 
Adult Bipolar Disorder 0.75% 1.34% 
Adult Other SMI diagnoses 0.62% 1.66% 
Adult Multiple SMI categories 0.38% 1.56% 
Total Adult SMI Diagnosis Subpopulation  7,637 25,011 
Children HMO (N=498,004) MP (N=616,651)
Childhood/Adolescent Major Depression 0.17% 0.36% 
Childhood/Adolescent Adjustment Reaction 0.95% 1.34% 
Childhood/Adolescent ADHD 1.34% 2.28% 
Childhood/Adolescent Disruptive Behavior 0.35% 0.43% 
Childhood/Adolescent Other SMI diagnoses 0.14% 0.30% 
Childhood/Adolescent Multiple SMI diagnoses 0.28% 0.65% 
Total Child/Adolescent SMI Diagnosis Sub-
population  16,040 32,974 
Standard Cost Rates 
Using the per-prescription amount paid for the MP claims for each NDC code and applying this 
average standard cost to each prescription, we computed standard cost estimates.  There were 23 
NDC codes in the HMO file where a standard cost could not be computed from MP data.  For 
these, the average amount paid for all MP claims covered by all the brand name and generic-
equivalent NDC codes for the specific formulary name were averaged to produce a standard rate.  
This was true for less than 0.20% of the HMO claims.   Actual costs could not be computed, due 
to the fact that the HMO statewide pharmacy claims database does not have cost data. The main 
assumption underlying this calculation is that, on the average, there are no differences between 
the HMO and MP condition in the quantity of drugs supplied in each prescription for the same 
NDC code.  Unfortunately, while we have quantity-dispensed data for the HMO condition, we 
do not have an equivalent measure for the MP condition.   
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Pharmaceutical Definitions.  Table 5 summarizes preferred drug classes that we combined to 
form the broader study drug groups.  Generic substitutions for each pharmaceutical listed are 
also included.   
Table 6: Correspondence Between AHCA Preferred Drug List Classes and Pharmaceutical 
Groupings used in This Study 
Preferred Drug 
List Class 
AHCA Therapeutic Class Study Drug Grouping 
H7T Anti-psychotic Non-phenothiazine in H7T Atypical Anti-psychotic 
H2S Serotonin-Specific Reuptake Inhibitors  SSRI Anti-depressants 
H7B 
H7C 
H7D 
H7E 
Alpha-2 Reuptake Inhibitors 
Serotonin-Norepinephrine Reuptake Inhibitors 
Norepinephrine-Dopamine Reuptake Inhibitors 
Serotonin-2 Antagonist Reuptake Inhibitors 
Newer Antidepressant 
H2V Anti-hyper kinesis Anti-hyper kinesis agents 
H2U 
H2X 
H7J 
Tri-cyclic Antidepressant 
Tri-cyclic Antidepressant/Antianxiety 
MAOI  
Other Anti-depressants 
H2G 
H7O 
H7P 
H7R 
H7S 
H7U 
Phenothiazine Anti-psychotic 
Non-phenothiazine Anti-psychotic-butyrophenones 
Non-phenothiazine Anti-psychotic-thioxanthenes 
Non-phenothiazine Anti-psychotic-diphenylbutylpiperidines  
Non-phenothiazines-dihydroindolones 
Non-phenothiazines-Dopamine and Serotonin 
Antagonists 
Other Anti-psychotics 
H2M Anti-mania Anti-mania  
H2F 
H2W 
Anti-anxiety 
Anti-psychotic/Anti-depressant combinations 
Other psychoactive 
 
Limitations 
 
Comparison of the financing conditions restricts the diagnostic condition definition to 
only those services where claims are available in the AHCA Statewide service claims database 
for both HMO and MP enrollees, which excludes services such as psychiatric in-patient care 
within the HMO networks. 
The statewide HMO pharmacy file has incomplete data (see Appendix 1).  We can 
assume the estimates presented here are the lower bound estimates of pharmacy use.  To help 
remove bias due to missing data, we removed eligibility and claims information for those people 
assigned to providers with missing pharmacy data from the analysis for those months where 
pharmacy data is missing for that HMO provider.  This slightly reduced the number of people, 
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eligible months, and diagnosed members in affected HMO plans, but should affect all 
calculations equally. 
 
Results 
 
Prevalence of SMI Diagnostic Categories by AHCA area.  The percent of enrollees with each 
child and adult diagnosis by area is presented in Table 7.  As can be seen in table 7, in all areas, 
adult HMO enrollees have a lower prevalence of SMI diagnoses than MP enrollees.   The 
percentage of adults with SMI in the MediPass condition seems particularly high in Areas 10 and 
11.  In Area 11, over 20% of the adult enrollees have an SMI diagnosis.  There are also fewer 
children diagnosed with SMI in the HMO condition compared to MediPass, however the 
difference is far less extreme than for adults.  
 Table 7: Prevalence of Adult and Child/Adolescent Severe Mental Illness by Diagnosis in Community Mental Health/Targeted 
Case Management Services  (Research Questions 1 and 2) 
Percent Total Adults with 
Schizophrenia Diagnosis 
in Financing Plan during 
Year  
Percent Total Adults with 
Major Depression 
Diagnosis in Financing 
Plan during Year  
Percent Total Adults with 
Bipolar Diagnosis in 
Financing Plan during 
Year  
Percent Total Adults with 
Other SMI Diagnosis in 
Financing Plan during 
Year  
Percent Total Adults with 
Multiple SMI Diagnoses 
in Financing Plan during 
Year  
Area HMO MP HMO MP HMO MP HMO MP HMO MP 
1 0.79%         1.69% 1.73% 2.98% 0.86% 1.16% 1.32% 1.70% 0.12% 0.47%
2 1.48%         1.98% 1.63% 2.18% 0.40% 1.00% 0.53% 0.81% 0.20% 0.54%
3 1.16%         1.72% 1.97% 3.18% 0.88% 1.08% 0.45% 0.57% 0.35% 0.59%
4 1.36%         2.39% 1.62% 2.94% 0.72% 1.26% 0.62% 1.36% 0.91% 2.31%
5 0.74%         2.06% 2.41% 5.07% 1.89% 3.06% 1.00% 2.45% 0.37% 2.07%
6 0.74%         1.95% 1.84% 2.91% 0.73% 1.09% 0.43% 1.02% 0.22% 0.36%
7 0.96%         2.35% 1.94% 3.39% 0.79% 1.53% 0.81% 1.46% 0.36% 1.01%
8 1.18%         1.72% 1.61% 2.70% 1.43% 1.71% 1.16% 1.11% 0.64% 0.68%
9 0.77%         2.01% 0.99% 2.62% 0.52% 1.02% 0.51% 1.62% 0.17% 0.61%
10 0.85%         3.76% 1.81% 5.68% 0.61% 1.68% 0.67% 2.70% 0.32% 2.83%
11 1.01%         3.71% 2.31% 9.39% 0.33% 1.21% 0.43% 2.74% 0.40% 3.19%
Percent Total Children 
with ADHD Diagnosis in 
Financing Plan during 
Year  
Percent Total Children 
with Major Depression  
Diagnosis in Financing 
Plan during Year  
Percent Total Children 
with Disruptive Behavior 
Diagnosis in Financing 
Plan during Year  
Percent Total Children 
with Other SMI Diagnosis 
in Financing Plan during 
Year  
Percent Total Children 
with Multiple SMI 
Diagnoses in Financing 
Plan during Year  
Area HMO MP HMO MP HMO MP HMO MP HMO MP 
1 1.33%         2.09% 0.17% 0.22% 0.42% 0.46% 0.12% 0.22% 0.12% 0.31%
2 1.59%         2.69% 0.16% 0.21% 0.75% 0.40% 0.08% 0.14% 0.48% 0.73%
3 1.43%         2.39% 0.23% 0.33% 0.30% 0.40% 0.14% 0.21% 0.35% 0.58%
4 1.67%         2.61% 0.17% 0.32% 0.22% 0.26% 0.29% 0.41% 0.54% 1.07%
5 1.41%         2.82% 0.14% 0.48% 0.23% 0.53% 0.24% 0.59% 0.17% 0.75%
6 1.17%         1.99% 0.14% 0.23% 0.18% 0.31% 0.08% 0.16% 0.08% 0.18%
7 1.76%         3.11% 0.16% 0.30% 0.54% 0.79% 0.16% 0.30% 0.39% 0.93%
8 1.23%         1.27% 0.10% 0.20% 0.24% 0.34% 0.16% 0.25% 0.30% 0.58%
9 0.50%         1.28% 0.14% 0.48% 0.27% 0.40% 0.09% 0.30% 0.24% 0.64%
10 0.74%         1.70% 0.15% 0.41% 0.60% 0.57% 0.14% 0.44% 0.38% 1.15%
11 1.59%         2.47% 0.22% 0.56% 0.35% 0.37% 0.10% 0.33% 0.25% 0.47%
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 Penetration of Recommended Drug Classes for Specific Diagnostic Groups  (Research 
questions 3-6). Analyses were conducted to determine the penetration of specific recommended drug 
classes for persons in each of the homogeneous diagnosis groups.   A person is classified as having 
received the drug if one claim for the drug was found during the fiscal year. 
Penetration of Anti-Psychotics in the Adult Schizophrenia Diagnostic Group.  Among MediPass 
recipients in the Adult Schizophrenia group, over 90% receive an anti-psychotic medication in every 
area of the state.  The rates for any anti-psychotic are more variable in the HMO group, varying from a 
low of 52% in Area 9 to 92% in Area 1.  Rates of utilization for atypical anti-psychotic agents are much 
lower than those for any anti-psychotic medication - averaging around 50% for the HMO financing 
condition and 66% for the MediPass condition.   On average across all areas, persons in the HMO 
condition are somewhat less likely to receive an atypical agent that persons enrolled in the MediPass 
condition.   
 
Table 8.  Penetration of Filled Prescriptions for Atypical Agents and Other Anti-psychotic 
Pharmaceutical Agents Among Adults Who Have a Diagnosis of Schizophrenia By Area and 
Financing Condition (Research Question 3) 
  
 
N in 
diagnostic 
subgroup by 
Area3
Total Penetration of 
Anti-psychotic 
pharmaceuticals for 
Adult Schizophrenia 
Group by Financing 
Plan during Year 
Penetration of Atypical 
pharmaceuticals for 
Adult Schizophrenia 
Group by Financing 
Plan during Year  
Penetration of Other 
Anti-psychotic 
pharmaceuticals for 
Adult Schizophrenia 
Group by Financing 
Plan during Year  
Area HMO MP HMO MP HMO MP HMO MP 
1 39 217 92.31% 92.63% 58.97% 52.53% 58.97% 64.98%
2 67 317 76.12% 94.32% 59.70% 60.88% 31.34% 54.89%
3 125 475 82.40% 93.68% 58.40% 59.16% 40.00% 60.84%
4 211 512 86.73% 91.41% 65.40% 64.26% 47.39% 52.54%
5 102 272 88.24% 96.69% 67.65% 78.31% 41.18% 48.53%
6 231 408 81.82% 93.63% 48.92% 69.12% 51.08% 53.19%
7 204 431 86.76% 95.13% 71.57% 76.10% 37.25% 42.46%
8 68 175 85.29% 92.00% 52.94% 68.00% 57.35% 50.29%
9 76 299 52.63% 93.31% 32.89% 64.55% 26.32% 59.87%
10 107 405 67.29% 94.32% 50.47% 75.80% 28.04% 49.63%
11 352 1793 58.24% 93.87% 35.51% 65.48% 31.25% 56.22%
Statewide (N=6,558) 76.11% 93.76% 53.22% 66.61% 39.76% 54.32%
                                                 
3 People in more than one condition or area during the course of the year are represented more than once in this analysis.  
Penetration is specific to the condition and area on date of prescription.  People may penetrate in more than one condition. 
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 Comparison of penetration rates of atypical and other anti-psychotic penetration rates shows that 
approximately 17-27% of the Adult Schizophrenia group penetrated both atypical and other anti-
psychotic medication over the course of the year. 
Penetration of Anti-Depressants in Adult Major Depression Diagnostic Group.  In Table 9, the 
overall penetration rate for antidepressants in the Adult Depression group is presented.  The rates for the 
use of any antidepressant is slightly lower than the penetration rate for anti-psychotics in the Adult 
Schizophrenia group.  Overall, 85% of adults in the Major Depression group were getting medications 
targeted to their illness.  Most persons, who received a prescription, were using SSRI Anti-depressants 
and Newer Antidepressants.   As with the atypical agents, substantial variability between areas occurs 
when contrasting the HMO and MP group.  Seven areas had at least a 10% difference in the rates for the 
two conditions.  Overall, persons in the MP condition were more likely to receive the SSRI or newer 
anti-depressants.  Less than 3% of the Adult Depression group received only the older antidepressants.  
The overlap between the SSRI/Newer classes and the other anti-depressants was between 8% and 11%. 
 
Table 9.  Penetration of Filled Prescriptions for SSRI Anti-depressants or Newer Agents 
Compared to Other Anti-depressant Pharmaceutical Agents Among Adults Who Have a 
Diagnosis of Depression by Area and Financing Condition (Research Question 4) 
  
 
 
N in 
diagnostic 
subgroup by 
Area4
Total Penetration of 
Anti-depressant 
pharmaceuticals for 
Adult Major 
Depression Group by 
Financing Plan during 
Year 
Penetration of SSRI 
Anti-depressant or 
Newer pharmaceuticals 
for Adult Major 
Depression Group by 
Financing Plan during 
Year 
Penetration of Other 
Anti-depressant 
pharmaceuticals for 
Adult Major 
Depression Group by 
Financing Plan during 
Year  
Area HMO MP HMO MP HMO MP HMO MP 
1 85 382 81.18% 87.43% 75.29% 85.34% 12.94% 13.09%
2 74 348 81.08% 87.07% 74.32% 82.76% 13.51% 13.79%
3 212 879 77.36% 87.37% 74.06% 82.94% 14.62% 19.00%
4 251 630 83.67% 90.00% 79.68% 87.62% 13.55% 17.30%
5 333 670 80.18% 90.75% 77.48% 88.66% 12.01% 16.12%
6 576 607 81.25% 85.50% 77.26% 81.22% 14.41% 18.29%
7 412 621 78.16% 88.41% 75.97% 85.67% 12.14% 11.11%
8 93 274 82.80% 89.05% 79.57% 87.59% 11.83% 16.42%
9 98 390 65.31% 87.18% 57.14% 82.05% 18.37% 19.23%
10 229 612 61.14% 82.68% 57.64% 78.92% 7.86% 12.58%
11 810 4534 48.27% 88.22% 45.80% 84.10% 5.06% 13.90%
Statewide N=12,249 70.34% 87.85% 66.97% 84.15% 10.94% 14.97% 
                                                 
4 People in more than one condition or area during the course of the year are represented more than once in this analysis.  
Penetration is specific to the condition and area on date of prescription.  People may penetrate in more than one condition. 
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 Penetration of Preferred Medications in Target Child/Adolescent Diagnostic Groups. Referring 
to Table 10, children or adolescents in the Major Depression group, have a much lower penetration of 
anti-depressant medication than adults with a Major Depression diagnosis.  Almost all of the use among 
children is for the SSRI Anti-depressants or Newer antidepressants.  HMO recipients with 
Childhood/Adolescent Major Depression in almost every area have far lower penetration of anti-
depressant agents than MediPass recipients with seven of the areas having a greater than 10% lower rate 
  
Table 10.  Penetration of filled prescriptions for SSRI/Newer medications for Child/Adolescent 
Depression and Anti-Hyperkinesis medication for Child/Adolescent ADHD by Area and 
Financing Condition  (Research Questions Question 5 & 6) 
  
 
 
 
N in diagnostic 
subgroup by 
Area 5
Total Penetration of 
Anti-depressant 
pharmaceuticals for 
Childhood/Adolescent 
Major Depression 
Group6 by Financing 
Plan during Year  
Penetration of SSRI 
Anti-depressants/Newer 
pharmaceuticals for 
Childhood/Adolescent 
Major Depression 
Group by Financing 
Plan during Year  
 
 
 
 
N in diagnostic 
subgroup by 
Area 
Total Penetration of 
Anti-hyper kinesis 
pharmaceuticals for 
Childhood/Adolescent 
ADHD Group7 by 
Financing Plan during 
Year  
Area HMO MP HMO MP HMO MP HMO MP HMO MP 
1 22 76 59% 40% 59% 68% 172 716 70% 79%
2 17 92 65% 70% 65% 57% 164 1157 57% 73%
3 67 250 42% 58% 40% 61% 421 1792 61% 77%
4 72 208 43% 62% 40% 59% 718 1700 52% 69%
5 51 166 61% 62% 61% 76% 501 966 68% 78%
6 127 137 49% 76% 46% 61% 1065 1207 68% 74%
7 111 184 52% 61% 52% 67% 1201 1930 59% 73%
8 21 80 52% 68% 52% 64% 249 515 69% 73%
9 51 267 25% 65% 25% 55% 182 707 50% 73%
10 74 145 36% 61% 36% 57% 354 600 41% 61%
11 225 628 22% 57% 22% 50% 1653 2759 26% 53%
Statewide N=2,856 40% 60% 39% 59% N=19,261 52% 69% 
 
of use in the HMO as contrasted with the MP condition.  For children or adolescents with ADHD, the 
penetration of anti-hyperkinesis pharmaceuticals is higher in the MP than in the HMO condition in every 
area of the state.   Rates of penetration are lower for the children in the HMO group than in the MP 
group in every area.   
                                                 
5 People in more than one condition or area during the course of the year are represented more than once in this analysis.  
Penetration is specific to the condition and area on date of prescription.  People may penetrate in more than one condition. 
6 May also include children or adolescents who have concomitant diagnoses of Affective Disorder.  Children with diagnoses 
of affective disorder only were excluded from this analysis due to a penetration rate of 20% or lower for all anti-depressants.  
Use of other psychoactive agents among this group of children will be examined in a later section. 
7 Does not include children or adolescents who have concomitant diagnoses of Major Depression. 
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 Standard Costs for All Drug Classes for Each Diagnostic Group.   
 These analyses refer to the data summarized in Table 11.  In every diagnostic group and for 
nearly every pharmaceutical, persons in the MediPass condition were more likely to be psychotropic 
pharmacy users than persons in the HMO condition.  In general, adults’ pharmacy expenditures exceed 
those for children and the use of atypical agents is clearly associated with increasing total costs.  Much 
of the difference between adults and children is explained by the relatively rare use of atypicals for 
children with depression, adjustment, disruptive or hyperactivity disorders.  However, for children with 
multiple diagnoses in the SMI group, atypical agents are quite commonly prescribed.   Given that these 
drugs were not developed for children’s disorders, their rate of utilization for children with complicated 
diagnostic profiles may be a concern.   
When standard cost rates are calculated per eligible month for those having access to a particular 
class of medication, persons in the MediPass Adult Schizophrenia group still have higher standard costs 
and filled prescriptions per user per month than those in the HMO Adult Schizophrenia group for both 
Atypical and other anti-psychotic medications.  Standard costs were found to be significantly lower for 
three of the six HMO groups in a multiple regression analysis controlling for age, race, gender, 
eligibility plan, and AHCA area (see Table 1 in Brief Report in Appendix 2) for atypical use in the Adult 
Schizophrenia group.  However, for two of the HMO plans the standard costs were found to be 
significantly higher than in the MediPass condition and in one HMO plan the difference was not 
significant. 
Standard cost per user per eligible month for all other diagnostic plans and pharmaceutical 
groups were either roughly equivalent or higher in the HMO financing plans compared to the MP 
financing plan.  In the multiple regression analysis for SSRI or Newer antidepressants, standard costs for 
adult persons with a depression diagnosis (Table 2 in Brief Report in Appendix 2), four of the six HMO 
financing plan groups had significantly higher standard costs.  In Table 11, the only other comparisons 
where the MediPass condition had substantially higher standard costs than the HMO condition was for 
atypical usage in children with multiple SMI diagnoses and other SMI diagnoses.  These two diagnostic 
groups contain children within the same diagnosis range of the Adult Schizophrenia group. 
From Table 11, it is clear that while access to most pharmaceutical classes is lower in the HMO 
financing plan than in the MediPass plan, once access is gained, utilization is equivalent or better for  
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 Table 11.  Statewide Penetration and Standard Cost Per Eligible Month for All Members of Adult 
and Child/Adolescent Diagnostic Groups for Each Type of Psychotropic Medication by Financing 
Plan 
Class of Medication for 
Each Diagnostic 
Category 
Penetration of 
pharmaceuticals for 
Diagnostic Group by 
Financing Plan during 
Year  
Standard Utilization 
rate Per Eligible Month 
in Plan for Users of 
Pharmaceutical Class 
 
Prescriptions Filled Per 
Eligible Month in Plan 
for Users of 
Pharmaceutical Class 
Adult Schizophrenia 
 
HMO 
N=1,5768
MP  
N=5,299 
HMO MP HMO MP 
Atypicals 53% 67% $208.54 $236.44 0.88 1.06
Other Anti-psychotics 40% 54% $25.38 $31.48 0.81 0.83
SSRI 24% 30% $58.22 $58.80 0.71 0.69
Newer Antidepressants 14% 18% $31.69 $29.53 0.73 0.61
Other Anti-depressants 5% 7% $9.43 $9.82 0.75 0.65
Anti-anxiety 16% 30% $23.38 $27.05 0.74 0.84
Anti-mania 5% 8% $14.34 $15.22 0.77 0.81
Adult Major 
Depression 
HMO 
N=3,167 
MP 
N=9,937 
HMO MP HMO MP 
SSRI 51% 65% $66.39 $53.96 0.79 0.65
Newer Antidepressants 37% 46% $40.69 $37.21 0.83 0.66
Other Anti-depressants 11% 15% $8.72 $7.88 0.71 0.60
Atypicals 26% 37% $155.86 $142.76 0.73 0.66
Other Anti-psychotics 16% 17% $10.24 $10.57 0.52 0.48
Anti-anxiety 34% 57% $29.05 $24.13 0.91 0.87
Anti-mania 6% 7% $15.96 $13.99 0.79 0.66
Adult Bipolar Disorder HMO  
N=1,242 
MP  
N=2,871 
HMO MP HMO MP 
Anti-mania 27% 32% $17.43 $15.93 0.94 0.84
Atypicals 40% 51% $189.49 $171.14 0.86 0.79
Other Anti-psychotics 19% 24% $15.13 $16.08 0.66 0.58
SSRI 43% 50% $70.00 $57.33 0.85 0.68
Newer Antidepressants 39% 43% $41.52 $36.88 0.83 0.70
Other Anti-depressants 7% 11% $9.73 $7.66 0.79 0.56
Anti-anxiety 35% 46% $31.07 $25.38 0.94 0.80
Adult All Other SMI 
Groups 
HMO  
N=1,652 
MP  
N=6,904 
HMO MP HMO MP 
Atypicals 58% 73% $214.19 $218.69 0.91 0.98
Other Anti-psychotics 31% 41% $19.62 $24.96 0.75 0.74
SSRI 41% 51% $66.79 $58.16 0.78 0.69
Newer Antidepressants 29% 35% $36.57 $36.83 0.75 0.66
Other Anti-depressants 9% 12% $11.72 $9.49 0.79 0.61
Anti-anxiety 26% 49% $32.88 $26.60 0.85 0.91
Anti-mania 14% 16% $16.41 $15.05 0.89 0.78
                                                 
8 People in more than one condition or area during the course of the year are represented more than once in this analysis.  
Penetration is specific to the condition and area on date of prescription.  People may penetrate in more than one condition. 
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 Table 11 continued 
Child/Adolescent 
Major Depression 
HMO 
N=835 
MP  
N=2,232 
HMO MP HMO MP 
SSRI 30% 44% $43.93 $43.05 0.56 0.54
Newer Antidepressants 16% 26% $32.43 $36.99 0.55 0.57
Other Anti-depressants 2% 4% $7.57 $7.07 0.55 0.47
Atypicals 16% 22% $114.68 $114.87 0.64 0.70
Other Anti-psychotics 4% 9% $5.97 $5.26 0.33 0.29
Anti-anxiety 8% 14% $37.30 $33.42 0.78 0.72
Anti-hyper kinesis 3% 9% $50.79 $25.48 0.59 0.47
Anti-mania 2% 4% $18.81 $18.61 0.74 0.72
Child/Adolescent 
ADHD 
HMO 
N=6,668 
MP 
N=14,037
HMO MP HMO MP 
Anti-hyper kinesis 52% 69% $36.55 $34.20 0.83 0.76
Atypicals 10% 16% $103.82 $97.63 0.76 0.70
Other Anti-psychotics 3% 7% $6.40 $4.45 0.35 0.26
SSRI 6% 12% $45.23 $40.22 0.59 0.51
Newer Antidepressants 8% 14% $30.71 $30.20 0.59 0.55
Other Anti-depressants 4% 6% $8.30 $7.76 0.64 0.57
Anti-anxiety 2% 3% $63.09 $42.22 0.67 0.47
Anti-mania 1% 2% $17.84 $17.34 0.73 0.69
Child/Adolescent 
Multiple Disorders 
HMO  
N=1,379 
MP  
N=4,012 
HMO MP HMO MP 
Anti-hyper kinesis 37% 53% $34.67 $35.59 0.78 0.76
Atypicals 22% 36% $112.50 $137.67 0.73 0.88
Other Anti-psychotics 4% 10% $9.51 $9.14 0.42 0.39
SSRI 16% 30% $42.80 $47.54 0.56 0.59
Newer Antidepressants 13% 26% $30.50 $34.31 0.54 0.57
Other Anti-depressants 3% 7% $7.13 $7.65 0.58 0.55
Anti-anxiety 2% 6% $45.02 $27.98 0.49 0.41
Anti-mania 3% 8% $15.55 $16.26 0.64 0.73
Child/Adolescent  
All Other SMI Groups 
HMO  
N=8,537 
MP  
N=12,693
HMO MP HMO MP 
Anti-hyper kinesis 10% 14% $33.47 $30.30 0.77 0.67
Atypicals 7% 14% $134.21 $140.28 0.81 0.82
Other Anti-psychotics 3% 7% $7.17 $8.86 0.35 0.34
SSRI 7% 12% $42.32 $41.09 0.55 0.52
Newer Antidepressants 4% 8% $32.40 $31.48 0.59 0.54
Other Anti-depressants 1% 3% $8.08 $7.39 0.53 0.51
Anti-anxiety 1% 3% $31.58 $27.47 0.55 0.47
Anti-mania 2% 4% $16.99 $17.17 0.75 0.73
 
most pharmaceutical classes for the HMO plan compared to the MediPass plan for all pharmaceutical 
classes except atypical usage among those persons with schizophrenia diagnoses. 
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 Formulary Analysis (Tables 12-17, Research Question 8).  We conducted a series of analyses to 
describe the specific prescribing patterns of each of the major HMO plans.  In Tables 12-17, HMOs 1, 2, 
3, and 4 represent single plans.  HMO Group A and HMO Group B each represent multiple smaller 
plans in geographical areas of the state.  The smaller HMOs were grouped in order to have sufficient 
sample sizes for the analyses. In these analyses HMO providers were identified through the provider ID 
listed on capitation payments for each member within a diagnostic group each month. Annual 
penetration and cost per user per month of all commonly prescribed drugs for each diagnostic group 
statewide as prescribed by either MediPass or specific HMO plans was calculated.  Tabled results are 
limited to prescribed pharmaceutical substances with at least a 20% penetration for one financing plan.  
Slightly lower penetration rates were used for the two depression groups due to the wide variety of anti-
depressants available.  Penetration and standard cost data that was based on observations of less than 6 
individuals are not reported. 
As seen in all other analyses, penetration of all pharmaceuticals examined was lower in most of 
the HMO financing plans than in MediPass. Across diagnostic categories and pharmaceuticals, standard 
costs per user per month of the most prescribed drugs appeared to be very similar across MP providers 
and the major HMO plans.  The variability among plans may be due to the low number of users in some 
of the HMO conditions.  It should be noted that while Table 11 indicated a substantial difference in 
standard costs between the two major financing plans, the analysis of specific pharmaceuticals in Table 
12 did not reflect this difference.  This may have been due to greater multiple AAP use in the MediPass 
condition. Comparisons of the two tables indicate that at least 16% of the adult persons in MP with 
schizophrenia diagnoses had multiple AAP use over the course of the year.  Thus, it is not surprising that 
standard costs for specific AAPs appear lower in MP relative to some of the HMOs.   
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 Table 12.  Specific Pharmaceuticals Most Commonly Used by the Adult Schizophrenia Group by Financing Provider Group 
  Atypical Zyprexa Atypical Risperidal Other Atypical 
Typical  
Anti-psychotics Anti-Anxiety 
Financing Group9
Penetration Standard 
Rate10
Penetration Standard 
Rate 
Penetration Standard 
Rate 
Penetration Standard 
Rate 
Penetration Standard 
Rate 
MP Providers (N=5,299) 34% $236.35      31% $143.39 18% $189.10 54% $31.48 30% $27.05
HMO 1 (N=260) 26% $281.73      27% $152.59 13% $121.32 49% $42.69 17% $28.36
HMO 2 (N=238) 18%         $269.58 29% $179.14 9% $242.66 42% $22.93 17% $28.42
HMO 3 (N=563) 31% $223.50      31% $127.09 12% $98.71 44% $19.85 15% $20.30
HMO 4 (N=146) 21%         $395.93 18% $175.83 5% $191.93 43% $29.15 16% $32.07
HMO Group A (N=332) 18%         $228.90 17% $100.24 6% $127.67 23% $22.25 14% $21.71
HMO Group B (N=151) 32% $188.69      29% $125.92 16% $139.07 32% $14.31 19% $20.04
 
Table 13.  Specific Pharmaceuticals Most Commonly Used by the Adult Depression Group by Financing Provider Group 
  SSRI Prozac SSRI Paxil SSRI Zoloft Other SSRI Anti-Anxiety 
Financing Group 
Penetration Standard 
Rate 
Penetration Standard 
Rate 
Penetration Standard 
Rate 
Penetration Standard 
Rate 
Penetration Standard 
Rate 
MP Providers (N=9,937) 21%         $66.19 24% $38.24 19% $38.47 14% $38.58 57% $24.13
HMO 1 (N=604) 13%         $97.43 23% $62.01 16% $48.38 7% $27.56 34% $31.53
HMO 2 (N=803) 17% $105.10        20% $66.88 18% $63.64 7% $46.86 34% $34.35
HMO 3 (N=773) 18% $89.09        17% $42.18 17% $43.05 10% $37.38 35% $29.76
HMO 4 (N=279) 14% $109.08        17% $71.39 13% $83.84 4% $56.42 28% $43.17
HMO Group A (N=670) 8%         $61.80 12% $36.38 8% $26.84 6% $33.17 24% $19.47
HMO Group B (N=382) 14%         $70.25 20% $36.54 15% $39.62 10% $39.29 38% $22.88
  NDRIS Wellbutrin SNRIS Effexor 
Other Newer  
Anti-depressants Atypical Zyrexa 
Atypical 
Risperidone 
Financing Group 
Penetration Standard 
Rate 
Penetration Standard 
Rate 
Penetration Standard 
Rate 
Penetration Standard 
Rate 
Penetration Standard 
Rate 
MP Providers (N=9,937) 34% $236.35      31% $143.39 18% $189.10 54% $31.48 30% $27.05
HMO 1 (N=604) 26% $281.73      27% $152.59 13% $121.32 49% $42.69 17% $28.36
HMO 2 (N=803) 18%         $269.58 29% $179.14 9% $242.66 42% $22.93 17% $28.42
HMO 3 (N=773) 31% $223.50      31% $127.09 12% $98.71 44% $19.85 15% $20.30
HMO 4 (N=279) 21%         $395.93 18% $175.83 5% $191.93 43% $29.15 16% $32.07
HMO Group A (N=670) 18%         $228.90 17% $100.24 6% $127.67 23% $22.25 14% $21.71
HMO Group B (N=382) 32% $188.69      29% $125.92 16% $139.07 32% $14.31 19% $20.04
                                                 
9 People in more than one condition or area during the course of the year are represented more than once in this analysis.  Penetration is specific to the condition 
and area on date of prescription.  People may penetrate in more than one condition. 
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10 Standard costs are rates per eligible month in financing plan for those persons using a particular substance in year. 
 Table 14.  Specific Pharmaceuticals Most Commonly Used by Other Adult Diagnostic Groups by Financing Provider Group 
Adult Bipolar  Anti-mania Atypical Zyprexa Atypical Risperidal 
Typical  
Anti-psychotics Anti-Anxiety 
Financing Group 
Penetration Standard 
Rate 
Penetration Standard 
Rate 
Penetration Standard 
Rate 
Penetration Standard 
Rate 
Penetration Standard 
Rate 
MP Providers (N=2,871) 32%       $15.93 27% $182.01 20% $112.36 24% $16.08 46% $25.38
HMO 1 (N=299) 26%       $20.35 18% $213.25 22% $131.00 16% $28.15 40% $32.99
HMO 2 (N=287) 27%       $20.98 19% $292.12 20% $155.55 18% $14.07 33% $48.14
HMO 3 (N=371) 28%       $16.83 20% $189.06 19% $123.45 22% $10.85 32% $28.91
HMO 4 (N=74) 28%       $17.21 8% $158.30 15% $162.06 20% $13.21 31% $23.98
HMO Group A (N=162) 14%       $13.65 14% $188.43 10% $91.89 14% $10.92 27% $24.79
HMO Group B (N=194) 31%       $12.45 22% $155.41 16% $114.06 15% $8.58 35% $17.97
Multiple and Other 
Adult SMI Groups  Atypical Zyprexa Atypical Risperidal Other Atypical 
Typical  
Anti-psychotics Anti-Anxiety 
Financing Group 
Penetration Standard 
Rate 
Penetration Standard 
Rate 
Penetration Standard 
Rate 
Penetration Standard 
Rate 
Penetration Standard 
Rate 
MP Providers (N=6,904) 40% $214.28      35% $124.55 23% $146.32 41% $24.96 49% $26.60
HMO 1 (N=322) 29% $266.14      27% $155.46 12% $164.22 35% $29.98 26% $42.32
HMO 2 (N=302) 23% $319.19      35% $204.70 13% $179.36 27% $23.19 26% $45.83
HMO 3 (N=543) 31% $220.58      27% $135.13 14% $120.24 36% $16.09 22% $29.36
HMO 4 (N=96) 27%        $319.46 27% $164.77   24% $25.42 22% $42.78
HMO Group A (N=298) 22% $202.12     16% $84.54 8% $96.35 19% $14.74 23% $27.09
HMO Group B (N=220) 35% $187.85      28% $135.07 19% $135.83 26% $10.25 28% $20.92
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 Table 15.  Specific Pharmaceuticals Most Commonly Used by the Child/Adolescent ADHD Group by Financing Provider 
Group 
  
Anti-hyperkinetic 
Ritalin 
Anti-hyperkinetic 
Adderall 
Other Anti-
hyperkinetics 
Financing Group 
Penetration Standard 
Rate 
Penetration Standard 
Rate 
Penetration Standard 
Rate 
MP Providers (N=14,037) 37%     $29.49 37% $30.26 9% $23.31
HMO 1 (N=1,3967) 20%     $29.24 33% $39.21 4% $34.17
HMO 2 (N=2,004) 23%     $37.68 32% $45.79 5% $32.31
HMO 3 (N=1,724) 32%     $28.10 27% $27.83 7% $19.66
HMO 4 (N=644) 14%    2% $35.38 17% $43.36 $34.53
HMO Group A (N=1,135) 15%     $20.10 11% $24.26 2% $15.71
HMO Group B (N=833) 25%     $28.30 31% $30.40 5% $23.04
 
Table 16.  Specific Pharmaceuticals Most Commonly Used by Child/Adolescent Major Depression Group by Financing 
Provider Group 
  SSRI Prozac SSRI Paxil SSRI Zoloft NDRIS Wellbutrin 
Financing Group 
Penetration Standard 
Rate 
Penetration Standard 
Rate 
Penetration Standard 
Rate 
Penetration Standard 
Rate 
MP Providers (N=2,232) 14%       $49.82 14% $32.87 15% $34.44 13% $30.67
HMO 1 (N=139)         14% $40.81 10% $20.61 5% $14.94
HMO 2 (N=236) 11% $80.04      13% $57.96 9% $45.94 7% $42.41
HMO 3 (N=234) 9%       $51.66 12% $28.79 7% $29.44 8% $24.12
HMO 4 (N=86) 7% $84.19          
HMO Group A (N=162) 6% $34.72 7% $23.68 6% $23.49 6% $22.91
HMO Group B (N=94) 10%       $33.91 13% $31.89 9% $42.99 18% $25.02
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Table 17.  Specific Pharmaceuticals Most Commonly Used by the Child/Adolescent Multiple SMI Group by Financing 
Provider Group 
Multiple and Other 
Adult SMI Groups  
Anti-hyperkinetic 
Ritalin 
Anti-hyperkinetic 
Adderall 
Other Anti-
hyperkinetics Atypical Zyprexa Atypical Risperidal
Financing Group11p 
Penetration Standard 
Rate 
Penetration Standard 
Rate 
Penetration Standard 
Rate 
Penetration Standard 
Rate 
Penetration Standard 
Rate 
MP Providers (N=4,012) 28%         $29.80 31% $30.92 7% $20.47 12% $145.95 24% $97.84
HMO 1 (N=260) 13%         $39.74 22% $37.45 3% $64.58 5% $198.01 13% $123.96
HMO 2 (N=341) 20%         $38.71 23% $36.84 3% $29.34 5% $131.42 14% $99.81
HMO 3 (N=402) 22%         $25.67 22% $27.08 5% $12.27 8% $123.66 16% $69.25
HMO 4 (N=73) 11%        $38.51 16% $56.56   18% $148.49
HMO Group A (N=266) 11%        $24.25 10% $27.57 5% $140.07 10% $67.58
HMO Group B (N=222) 18%       $30.90 21% $29.69 5% $19.71 4% $107.04 14% $80.25
 
  
                                                 
11 People in more than one condition or area during the course of the year are represented more than once in this analysis.  Penetration is specific to the condition 
and area on date of prescription.  People may penetrate in more than one condition. 
 Conclusions 
 
Proportions of people accessing Community Mental Health or Targeted Case Management 
services within the diagnostic sub-groups of this study appear to be much higher in the MediPass than in 
the HMO conditions.  This may not reflect true differences in total proportions in these diagnostic sub-
groups within plans because we have not included claims for inpatient or physician mental health 
services. Penetration of mental health pharmaceuticals across a broad range of diagnostic sub-groups 
and pharmaceutical classes appears to be higher in the MediPass as compared to the HMO condition.  
This finding may be partially due to data quality issues, but overall, this finding appears to be consistent 
across areas and plans. 
While prevalence of SMI diagnoses is lower in the HMO financing plans compared to MediPass, 
and penetration of most pharmaceutical classes is lower in the HMO financing plans compared to 
MediPass, once access to a pharmaceutical class is obtained, the utilization rates are comparable or 
higher for the HMO financing plan.  The exception to this is the lower standard rate for AAP medication 
for persons with a schizophrenia diagnosis in some financing plans.  Prevalence of SMI diagnoses in the 
HMO financing plan may be partially under-represented due to the methodological limitations inherent 
in using only community mental health and targeted case management claims to establish the diagnostic 
groups.  However, there may be selection factors that limit the SMI population within the HMO 
financing plan.  These cannot be determined with these data. 
Penetration differences between pharmaceutical classes within the HMO financing plan may be 
due to three factors.  Either the HMO financing condition has greater numbers of people with SMI 
diagnoses that do not require medication, or the HMO plans are better able to identify those that do not 
require medication, or there is some factor that prevents access to some that need it. 
Once persons in the HMOs have access to pharmaceuticals, for most diagnostic groups, there 
does not appear to be limited utilization for pharmaceuticals other than AAPs.  This may be due to better 
management of poly-pharmacy AAP usage, as there does not appear to be much difference in plans for 
standard costs for specific AAP usage. 
The finding that HMOs control cost by limiting access to more expensive medications is 
consistent with findings from other studies of managed behavioral health care.  What is still unknown is 
what effect limited access to more expensive medications has on health outcomes in the Medicaid 
population.  If more expensive medications like Zyprexa are more effective than less expensive atypical 
medications, then HMO enrollees may have worse outcomes than persons in MediPass.  If, if on the 
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 other hand, expensive medications are no more effective than less expensive agents, than the HMO 
practice of prescribing less expensive agents controls cost without increasing harm.  In a future study, 
we will investigate the effect of anti-psychotic agents on resource utilization and health outcomes for 
persons with SMI in order to be able to answer questions about the consequences of limiting access to 
more expensive medications.  
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 Appendix 1 
Description of Problems with The Statewide HMO Pharmacy files 
 
There were a number of problems with the Statewide HMO files that should be brought to the attention 
of anyone intending to use them for research purposes.   
 Many of the NDC codes in the file are not in the correct NDC-11 format, but can be fixed by 
either removing or inserting leading zeros.  In the cases where leading zeros were removed, the 
first 9 characters of the NDC codes can be used to identify manufacturer and substance, but the 
last 2 digits, are not usable. 
 In at least one of the disks identified through the disk id variable, none of the recipient codes 
matched those codes found in the FY 2000-2001 eligibility file, which probably indicates that 
this code has been corrupted in some way.  There are many recipient codes found in this file that 
are not found in the eligibility file, but most of the recipients in the HMO pharmacy files match 
90% or better.  Except in the case of St. Augustine, Quarter 2 2001, we are assuming that the 
percentages of non-eligible recipients are not problematic. 
 Because files were apparently submitted on a quarterly basis, early submission of claims from 
HMOs sometimes resulted in records for an entire month being missing.  This is usually only the 
case for the last month of the quarter.  In the case of Wellcare Q1 2001, the entire quarter is 
missing. 
 Records for the tests of this file were limited to fill dates of July 1, 2000- June 30, 2001.  There 
were records outside of this date range. 
 
 
Due to the problems identified in the table on the next page, recommend that the eligible recipients for 
the following providers in the following months be eliminated: 
 
0150169 Wellcare Jan-Mar 2001 
0150207 St. Augustine Apr-June 2001 
0150223 Florida 1st  Jul-Sep 2000 
0152013 United Health March 2001 
0152196 PCA Family Sept 2000 all areas except Area 6- will use Area 6 HMO pharmacy file for 
this month 
0152374 JMH Health March 2001 
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 Here is the breakdown of the problems in this file: 
Plan Number and 
Description Disk Ids  
    
 
    
    
    
Records 
% of records 
with bad NDC 
codes 
Unique 
Recipients 
% of 
Recipients in 
eligibility 
FY00-01 file 
Months with 
Data Missing Comments/Fixes 
0150053-Physicians Care 
Plan   PHY00Q3-PHY01Q2 630,382 73,259 93.5%  
0150070-Discovery Plan   HPS00Q3-HPS01Q2 44,702 4,791 94.3%  
0150169-Wellcare HMO, 
Inc   STW00Q3-STW01Q2 759,259 84,339 94.3%Jan-Mar 2001 
STA01Q1 is a duplicate of STA00Q4, so the 
real STA01Q1 is completely missing  
0150177-Foundation 
Health Plan   FOU00Q3-FOU01Q2 174,150 18.07% 20,651 91.3% 
All bad NDC codes are just missing leading 
0's and are in FOU01Q2- fixable  
0150185-Neighborhood 
Health Plan, Inc   NEI00Q3-NEI01Q2 89,400 10,256 86.1%
0150193-Healthease   HEA00Q3-HEA01Q2 920,943 77.96% 85,906 94.1% 
All bad NDC codes are just missing leading 
0's present in all disks- fixable  
0150207-St. Augustine 
Health Care, Inc   STA00Q3-STA01Q2 111,654 44.17% 15,809 61.6%
Apr-June 2001 
not usable 
All bad NDC codes have extra leading zero 
and are missing last digit of 11-digit NDC 
code- fixable and usable because our 
classification is based on first 9 digits.  All bad 
codes are in STA00Q3 and STA00Q4.  None 
of the recipient codes in STA01Q2 matched 
the eligibility data.  
0150223-Florida 1st 
Health Plans, Inc.   FL100Q3-FL101Q2 34,243 79.86% 3,716 70.3%Jul-Sep 2000 
All bad NDC codes are just missing leading 
0's present in all disks- fixable.  In Q3 2000, 
there are only 354 records, compared to 
11,000 typically  
0150258-Healthy Palm 
Beaches, Inc   HEP00Q3-HEP01Q2 13,332 2,482 87.5%
0150274 BEA00Q3-BEA01Q2 53217 8,787 75.0%
0152005-Preferred 
Medical Plan, Inc.   PRE00Q3-PRE01Q2 31,823 5,382 93.5% 
All Bad NDC codes are just missing leading 
0's and are in UHP01Q2  
0152013-United Health 
Care Plans   
UHP00Q3, UHP01Q2, 
URA00Q4, URA01Q1 115,123 18.21% 8,385 95.0%Mar 2001 
This month has 714 records compared to a 
normal total near 10,000  
0152056-United Health 
Care Plans   URA00Q3-URA01Q2 286,634 24,158 92.4%
0152196-Pca Family 
Health Plan   HUM00Q3-HUM01Q2 327,108 37,982 95.0%Sep 2000 
September has 694 records compared to about 
30,000 in most months.    
0152374-Jmh Health Plan  JMH00Q3-JMH01Q2   51,264 5,343 88.2%Mar 2001
March 2001 has only 911 records compared to 
the usual 4000 per month  
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 Appendix 2 
 
Brief Report of the Statewide Penetration and Standard Cost of Psychotropic Medications 
Study:  A Sub-Study of the Agency for Health Care Administration (AHCA) Project 
 
Mary Rose Murrin, M.A., Neil Jordan, Ph.D., and David L. Shern, Ph.D. 
 
(This brief report is an inferentially based statistical study, whereas the main body of this report 
presented earlier is a descriptive study.) 
 
Background 
As part of a more extensive evaluation of Florida’s Medicaid prepaid mental health program 
(PMHP), the Florida Mental Health Institute has analyzed psychotropic drug use patterns for AHCA 
Area 6 (Tampa Bay region) enrollees.  In particular, we have been interested in the relationship 
between financing condition and access to newer, more expensive psychotropic medications for 
persons with schizophrenia or major depression.    
To date our findings in Area 6 suggest that HMO enrollees with these mental disorders have 
less access to newer, more expensive psychotropic medications than enrollees in the PMHP.  Using 
penetration rates as a proxy measure of access, we found that HMO enrollees with schizophrenia 
had a much lower penetration rate of filled prescriptions for atypical agents than PMHP enrollees 
with schizophrenia.  We also found that HMO enrollees with major depression had a slightly lower 
penetration rate for filled prescriptions for SSRI anti-depressants than PMHP enrollees with 
schizophrenia (Shern, et al., 2002; Shern, et al., 2001; Shern, et al., 2000; Shern, et al., 1999).   We 
have interpreted these differences in penetration rates to be a function of the differential risk 
arrangements that characterize the two financing conditions.  HMOs are at risk for prescription drug 
expenditures, while the PMHP is not at risk for these expenditures. 
What remains unknown is the extent to which the financing condition effect on access to 
expensive psychotropic medications in Area 6 is unique to that area or may be mitigated by other 
factors.  In this study, we address these unknowns by expanding the scope of our previous analyses 
in several ways.  First, we included statewide data to determine if there is an area effect on access to 
expensive psychotropic medications.  Second, we also analyzed children, with a particular focus on 
children with ADHD.  Finally, we expanded the analysis to include other commonly used, less 
expensive psychotropic medications for each mental disorder to determine if access to medications 
varied by relative “expensiveness” of the medication.   
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 Policy questions directly addressed in this summary include statewide differences in access 
to particular drug classes for HMO enrollees versus MediPass enrollees, differences in the estimated 
per member per month (PMPM) utilization rates for each drug within a class, differences in access 
to these pharmaceuticals across HMOs, and penetration rates by age and diagnostic group.  
Additional policy questions addressed in the main report include factors associated with access to 
pharmaceuticals within specific diagnostic groups: atypical use for adult schizophrenia, SSRI/newer 
anti-depressant use for adult depression, and anti-hyperkinetic use by adolescents and children with 
ADHD. 
 
Methods 
 The study population includes all persons enrolled in Medicaid during FY 2000-2001 who 
were age 1-64 in the AFDC and SSI eligibility programs or age 1-20 in the Foster Care and SOBRA 
eligibility programs, and had a non-zero capitation payment for PMHP, MediPass, or an HMO.  
From that population, we selected all enrollees with claims for community mental health or targeted 
case management services with particular mental health diagnoses to be included in our SMI 
population.    
We then established definitions for HMO provider, penetration rate, and standard cost.  
Because enrollees may have changed HMOs during the study period, we defined an enrollee’s 
HMO provider for each month as the provider who received that enrollee’s monthly capitation 
payment.  Penetration rate was defined as the number of enrollees who had at least one claim during 
the year for a particular medication divided by total enrollees in the group.  Standard costs were 
based on the average costs per prescription for specific dosages and were derived from MediPass 
cost data.   
This report is a brief summary of 18 analyses (6 per major type of psychotropic agent).  The 
penetration analyses presented in each of the figures are not adjusted for any other factors.  The 
standard costs PMPM figures summarize analyses based on total population data case-mix adjusted 
for eligibility status and eligibility age groups, which equates the groups on capitation payment 
structure, where applicable.  The tables in the Appendix are summaries of logistic and linear 
regression models.  These models are statistically adjusted to control for eligibility status, eligibility 
age groups, months of eligibility, race, gender, and Medicaid Area.  All bullets are referenced to 
indicate the specific analysis discussed. 
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 Use and Standard Costs of Atypical Anti-psychotics 
 Figure 1.  Statewide Penetration of Atypical Anti-psychotic Medication  
for Entire SMI Sample By Financing Plan 
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• Among all persons with SMI, individuals in Medicaid HMOs had less access to atypical 
anti-psychotic agents than individuals in MediPass (see Figure 1).  HMO penetration 
rates for atypical anti-psychotic agents ranged from 15% to 23%, while 34% of 
MediPass beneficiaries filled a prescription for an atypical anti-psychotic agent. 
• Among all adults with schizophrenia, individuals in Medicaid HMOs had less access to 
atypical anti-psychotic agents than individuals in MediPass, controlling for all other 
factors.  The odds that an HMO enrollee with schizophrenia filled at least one 
prescription for an atypical anti-psychotic agent were approximately half that of 
enrollees with schizophrenia in MediPass (see Appendix Table 1). 
• Besides being in MediPass, several variables were significantly related to any atypical 
anti-psychotic usage for adults with schizophrenia.  Controlling for all other factors, 
persons who were on SSI, white, or age 21-54 were more likely to have used an atypical 
anti-psychotic agent than persons on TANF, minorities, or persons age 55 or older, 
respectively (see Appendix Table 1).   
• Medicaid Area was also significantly related to any atypical anti-psychotic usage (see 
Appendix Table 1). 
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Figure 2.  Statewide Standard PMPM12 Cost of Atypical Medications for Entire SMI Population By 
Financing Plan and Medication (Each pharmaceutical case-mix adjusted separately by eligibility and age 
group to equate financing plans) 
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 • Standard costs per member-month for individuals in Medicaid HMOs were less for 
Zyprexa than for MediPass enrollees (see Figure 2).  This lower cost could reflect either 
a lower likelihood of getting Zyprexa or a lower dosage per prescription or a 
combination of the two factors.  The cost of Zyprexa13 ranges from $158-$393 per 
prescription, compared to costs ranging from $91-$265 per prescription for other 
commonly prescribed atypical anti-psychotic agents. 
• Among adults with schizophrenia who used any atypical anti-psychotic agents, there 
were several significant predictors of standard cost, controlling for all other factors.  
Females and African-Americans had lower standard costs than males and whites, 
respectively.  Other minorities also had lower standard costs than whites (see Appendix 
Table 1). 
                                                 
12 PMPM totals were based on member months for entire study population, while costs were totaled only for those in the 
SMI population.  Case mix adjusted total for all atypicals as a group may not match the sum of case mix adjusted totals 
for each pharmaceutical separately shown in this figure. 
13 Average costs per prescription were obtained from MediPass data and were calculated as the total amount paid for 
each NDC code divided by the number of prescriptions dispensed for that code. 
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 • Several HMOs had significantly lower standard costs among adults with schizophrenia 
who used atypical anti-psychotic agents, controlling for all other factors (see Appendix 
Table 1). 
• Medicaid Area had a significant overall effect on standard cost of atypical anti-psychotic 
agents among adult atypical users with schizophrenia (see Appendix Table 1).  
 
Figure 3.  Statewide Penetration of Atypical Medications By Diagnostic and Age Groups 
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• Nearly two-thirds of adults with schizophrenia used an atypical anti-psychotic agent (see 
Figure 3). 
• Usage of atypical anti-psychotic agents was quite common among adults with other 
mental disorders.  The penetration rate ranged from 35% for persons with depression to 
72% for adults with ‘Other Adult SMI’ (mood disorders, other psychotic disorders, or 
multiple disorders) (see Figure 3). 
• Usage of atypical anti-psychotic medications was surprisingly common in children.  The 
penetration rate ranged from 11% for children with ‘Other Child SMI’ (conduct, bipolar, 
or affective disorder) to 33% for children with multiple disorders.  About 15% of 
children with ADHD used an atypical anti-psychotic medication (see Figure 3). 
• Many children under age 14 used atypical anti-psychotic agents (see Figure 3).  
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 Use and Standard Costs of SSRI or Newer Anti-depressants 
Figure 4.  Statewide Penetration of SSRI and Newer Anti-depressant Medications  
for Entire SMI Sample By Financing Plan 
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 • Among all persons with SMI, individuals in Medicaid HMOs had less access to SSRI or 
newer anti-depressant medications than individuals in MediPass (see Figure 4).  HMO 
penetration rates for SSRI or newer anti-depressants ranged from 17% to 31%, while 
45% of MediPass beneficiaries filled a prescription for an SSRI or newer anti-
depressant. 
• Among adults with depression, individuals in Medicaid HMOs had less access to SSRI 
or newer anti-depressant agents than individuals in MediPass.  The likelihood that an 
HMO enrollee with depression filled at least one prescription for an SSRI or newer anti-
depressant agent was between 1.4 and 5.3 times less than that of enrollees with 
depression in MediPass (see Appendix Table 2), controlling for all other factors.  
• Besides being in MediPass, several variables were significantly related to any SSRI or 
newer anti-depressant usage, controlling for other factors.  Persons who were on SSI, 
white, or female were more likely to have used an SSRI or newer anti-depressant than 
persons on TANF, African Americans, or males, respectively (see Appendix Table 2).   
• Medicaid Area had a significant overall effect on the penetration rate of anti-depressants 
among adults with major depression (see Appendix Table 2). 
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 Figure 5.  Statewide Standard PMPM14 Cost of SSRI and Newer Anti-depressant Medications for 
Entire SMI Sample By Financing Plan and Medication  
(Case-mix adjusted by eligibility and age group to equate financing plans) 
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• Standard costs per member-month for individuals in Medicaid HMOs were less for 
Prozac, Effexor, Wellbutrin, and ‘Other Newer’ anti-depressants than for MediPass 
enrollees (see Figure 5).  This difference in standard cost could reflect lower likelihood 
of getting these medications or lower dosages per prescription.  The average cost per 
prescription for Prozac and Effexor in MediPass ranged from $36-$153, while the 
average cost per prescription for the other commonly prescribed SSRI or newer anti-
depressants ranged from $26-$73. 
• Among adults with depression who used any SSRI or newer anti-depressants there were 
several significant predictors of standard cost besides financing condition, controlling for 
all other factors.  Females, whites, and persons on SSI had higher standard costs than 
males, blacks and other minorities, and persons on TANF, respectively (see Appendix 
Table 2). 
• Medicaid Area had a significant overall effect on standard cost of anti-depressant agents 
among adults with depression.  (see Appendix Table 2). 
                                                 
14 PMPM totals were based on member months for entire study population, while costs were totaled only for those in the 
SMI population. 
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 Figure 6.  Statewide Penetration of SSRI and Newer Anti-depressant Medications  
By Diagnostic and Age Groups 
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• SSRI or newer anti-depressant usage was most common in persons with major 
depression.  Over 80% of adults with major depression used an anti-depressant (see 
Figure 6). 
• Usage of SSRI or newer anti-depressants was also quite common among adults with 
other mental disorders.  The penetration rate ranged from 39% for persons with 
schizophrenia to 70% for adults with bipolar disorders (see Figure 6). 
• Usage of SSRI or newer anti-depressants was also quite common in children.  Over 50% 
of children with depression used SSRI or newer anti-depressants, while over 40% of 
children with multiple disorders used SSRI or newer anti-depressants.  More than 20% 
of children with ADHD used an SSRI or newer anti-depressant (see Figure 6).  
• A substantial number of children using SSRI or newer anti-depressant agents were 
between the ages of 6 and 13 (See Figure 6). 
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 Use and Standard Costs of Anti-hyperkinetic Medications 
Figure 7.  Statewide Penetration of Anti-hyperkinetic Medications for Entire SMI Sample  
By Financing Plan 
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 • Among all persons with SMI, individuals in Medicaid HMOs had less access to anti-
hyperkinetic medications than individuals in MediPass, although the difference was far less 
than in previous analyses (see Figure 7).  HMO penetration rates for anti-hyperkinetic 
agents ranged from 9% to 23%, while 25% of MediPass beneficiaries filled a prescription 
for an anti-hyperkinetic agent.   
• Among children with ADHD, children in Medicaid HMOs had less access to anti-
hyperkinetic medications than individuals in MediPass.  An ADHD child in an HMO was 
from 1.2 to 3.0 times less likely to have filled at least one prescription than an ADHD child 
in MediPass (see Appendix Table 3). 
• Besides being in MediPass, several variables were significantly related to any anti-
hyperkinetic usage.  Children who were in Foster Care or SSI, white, or male were more 
likely to have used an anti-hyperkinetic agent than children in TANF, black children, or 
girls, respectively (see Appendix Table 3).   
• Medicaid Area was also significantly related to any anti-hyperkinetic usage (see Appendix 
Table 3). 
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 Figure 8.  Statewide Standard PMPM15 Cost of Anti-hyperkinetic Medications for Entire SMI 
Sample By Financing Plan and Medication  
(Case-mix adjusted by eligibility and age group to equate financing plans) 
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• Standard costs per member per month for persons in Medicaid HMOs were lower for Ritalin 
than among MediPass enrollees (see Figure 8) and lower for Adderall in some of the HMOs 
than for MediPass enrollees.  This difference could be due either to a lower likelihood of 
getting a prescription or lower dosages per prescription or a combination of these factors.  
The cost for Ritalin and Adderall ranged from $12 to $73 per prescription.  
• Among children with ADHD who used any anti-hyperkinetic agents, there were several 
significant predictors of standard cost besides being in MediPass, controlling for all other 
factors.  Males, whites, and persons in SSI, SOBRA, or Foster Care had higher standard 
costs than females, blacks and other minorities, and persons on TANF, respectively (see 
Appendix Table 3). 
• Medicaid Area had a significant overall effect on standard cost of anti-hyperkinetic agents 
among children with ADHD who used any hyper-kinetic medication (see Appendix Table 3). 
                                                 
15 PMPM totals were based on member months for entire study population, while costs were totaled only for those in the 
SMI population. 
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 Figure 9.  Statewide Penetration of Anti-hyperkinetic Medications By Diagnostic and Age Groups 
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• Anti-hyperkinetic use was most common in persons with ADHD.  Nearly 65% of 
children with ADHD used an anti-hyperkinetic agent (see Figure 9). 
• Usage of anti-hyperkinetic agents was somewhat common among children with other 
mental disorders.  The penetration rate was between 10% and 17% for children with 
disruptive behavior, depression, or adjustment reaction.  Nearly half of all children with 
multiple disorders used an anti-hyperkinetic agent (see Figure 9). 
• Usage of anti-hyperkinetic medications was rare (6%) in adults (see Figure 9).   
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 Conclusions and Policy Implications 
• For all three pharmaceutical classes analyzed, controlling for a number of other factors, 
HMO enrollees had significantly less access to medication than MediPass enrollees. 
• Where there were choices among specific pharmaceuticals within classes with differing 
average costs per prescription, the more expensive psychotropic medications within a class 
had lower PMPM standard costs for HMO enrollees compared to MediPass enrollees.   
• African-Americans and other minorities had lower access to psychotropic medications and, 
among those who used such medications, lower standard costs per month.  
• Adult SSI recipients and child Foster Care recipients had higher access and higher standard 
costs per month than TANF recipients for all three-drug classes. 
• Penetration rates and standard costs per month for all three-drug classes varied by Medicaid 
Area. 
• Among HMO enrollees, penetration rates and standard costs differed by HMO plan. 
 
The differences between HMO and MediPass PMPM medication costs may be explained by 
several factors.  Our data showed a lower prevalence of SMI diagnoses for HMO enrollees than for 
MediPass enrollees, less access given a diagnosis, and lower standard costs given access for Adults 
with Schizophrenia using Atypical anti-psychotic medication.   Another factor may be the higher 
percentages of African-Americans within the HMO population compared to MediPass.  Further 
study is needed into each of these findings to ascertain the underlying causes for these asymmetries.  
The finding that HMOs control cost by limiting access to more expensive medications is 
consistent with findings from other studies of managed behavioral health care.  What is still 
unknown is what effect limited access to more expensive medications has on health outcomes in the 
Medicaid population.  If more expensive medications like Zyprexa are more effective than less 
expensive atypical medications, then HMO enrollees may have worse outcomes than persons in 
MediPass.  If, if on the other hand, expensive medications are no more effective than less expensive 
agents, than the HMO practice of prescribing less expensive agents controls cost without increasing 
harm.  In another study, we are investigating the effect of anti-psychotic agents on resource 
utilization and health outcomes for persons with SMI in order to be able to answer questions about 
the consequences of limiting access to more expensive medications. 
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 Table 1.   Summary of 3 Regression Analyses 
(1) Logistic Regression Modeling Prevalence of Schizophrenia in Adult Population 
(2) Logistic Regression Modeling Penetration of Atypical Medication in Adult Schizophrenia 
(3) Linear Regression Modeling Standard Cost of Atypical Medication in Adult Schizophrenia 
Atypical Users 
 
Effect 
Odds Ratio for 
Prevalence 
Model 
Odds Ratio for 
Penetration 
Model 
Regression 
Coefficient for 
Standard Cost 
Model 
Months Eligible 1.10***16 1.04***   
Age 21-54 vs. Age 55+ 1.97*** 1.45***   13.73 
SSI vs. AFDC 66.84*** 2.14***   37.89 
Race:  Black vs. White 1.58*** 0.58*** -54.88*** 
Race:  Other vs. White 1.14*** 0.85    * -29.77*** 
Gender: Female vs. Male 0.54*** 1.13    * -13.82  ** 
Medicaid Area 02 vs. 0117 1.23    * 1.45    * -17.25 
Medicaid Area 03 vs. 01 1.18    * 1.28 -20.34 
Medicaid Area 04 vs. 01 1.29*** 1.68*** -19.73 
Medicaid Area 05 vs. 01 1.08 2.84***   39.97    * 
Medicaid Area 06 vs. 01 1.06 1.61  **   13.27 
Medicaid Area 07 vs. 01 1.27  ** 2.93***     3.92  
Medicaid Area 08 vs. 01 1.17 1.59    *   21.76 
Medicaid Area 09 vs. 01 1.18    * 1.40    *   20.81 
Medicaid Area 10 vs. 01 1.56*** 2.55*** -  0.37 
Medicaid Area 11 vs. 01 2.28*** 1.56** -11.01    
HMO 1 vs. MediPass 0.54*** 0.62***   38.90  ** 
HMO2 vs. MediPass 0.55*** 0.50***     1.24 
HMO3 vs. MediPass 0.76*** 0.90 -19.34     * 
HMO 4 vs. MediPass 0.90 0.55  **   39.60    * 
HMO Group A vs. MediPass 0.48*** 0.33*** -36.14     * 
HMO Group B vs. MediPass 0.54*** 0.74 -32.65     * 
 
 
                                                 
16 ***  p<.001, ** p<.01, * p<.05 
17 Selection of Area 1 as the comparison Area was arbitrary.  Overall area effect was significant in all regression 
equations. 
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 Table 2.   Summary of 3 Regression Analyses 
(1) Logistic Regression Modeling Prevalence of Depression in Adult Population 
(2) Logistic Regression Modeling Penetration of SSRI/Newer Anti-depressant Medication in Adult 
Depression 
(3) Linear Regression Modeling Standard Cost of SSRI/Newer Anti-depressant Medication in Adult 
Schizophrenia SSRI/Newer Anti-depressant Users 
 
Effect 
Odds Ratio for 
Prevalence 
Model 
Odds Ratio for 
Penetration 
Model 
Regression 
Coefficient for 
Standard Cost 
Model 
Months Eligible 1.06***18 1.09***   
Age 21-54 vs. Age 55+ 1.10*** 0.99 -  0.99 
SSI  vs. AFDC 4.06*** 1.32***    7.38*** 
Race:  Black vs. White 0.44*** 0.49*** -19.25*** 
Race:  Other vs. White 1.07** 0.97 -  5.09*** 
Gender: Female vs. Male 2.71*** 1.58***    3.13  ** 
Medicaid Area 02 vs. 0119 0.82* 0.83 -15.95*** 
Medicaid Area 03 vs. 01 1.10 0.83 -11.50*** 
Medicaid Area 04 vs. 01 0.98 1.31 -  7.24    * 
Medicaid Area 05 vs. 01 1.43*** 1.29 -  6.96    * 
Medicaid Area 06 vs. 01 0.97 0.84 -  5.01   
Medicaid Area 07 vs. 01 1.05 1.03 -13.01*** 
Medicaid Area 08 vs. 01 0.82** 1.18 - 6.02 
Medicaid Area 09 vs. 01 0.88 0.75 - 7.77     * 
Medicaid Area 10 vs. 01 1.72*** 0.69    * - 5.78 
Medicaid Area 11 vs. 01 2.95*** 0.72    * -16.97*** 
HMO 1 vs. MediPass 0.63*** 0.46***   23.55*** 
HMO2 vs. MediPass 0.83*** 0.63***   23.38*** 
HMO3 vs. MediPass 0.67*** 0.58***   10.70*** 
HMO 4 vs. MediPass 0.59*** 0.71    *   24.46*** 
HMO Group A vs. MediPass 0.37*** 0.19*** -  1.47 
HMO Group B vs. MediPass 0.66*** 0.57*** -  2.60 
 
                                                 
18 ***  p<.001, ** p<.01, * p<.05 
19 Selection of Area 1 as the comparison Area was arbitrary.  Overall area effect was significant in all regression 
equations. 
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 Table 3.   Summary of 3 Regression Analyses 
(1) Logistic Regression Modeling Prevalence of ADHD in Children Population 
(2) Logistic Regression Modeling Penetration of Anti-hyperkinetic Medication in Child/Adolescent 
ADHD 
(3) Linear Regression Modeling Standard Cost of Anti-hyperkinetic Medication in 
Child/Adolescent ADHD in Anti-hyperkinetic Medication Users 
 
Effect 
Odds Ratio for 
Prevalence 
Model 
Odds Ratio for 
Penetration 
Model 
Regression 
Coefficient for 
Standard Cost 
Model 
Months Eligible 1.04***20 1.12***   
Age 1-5 vs. Age 14-20 0.83*** 1.22*** -8.00*** 
Age 6-13 vs. Age 14-20 4.08*** 2.49***  2.34** 
Foster Care vs. AFDC 3.94*** 1.51***  6.93*** 
SOBRA vs. AFDC 0.73*** 1.11  **  2.63*** 
SSI vs. AFDC 4.98*** 1.71***  3.39*** 
Race:  Black vs. White 0.59*** 0.51*** -9.37*** 
Race:  Other vs. White 0.66*** 0.79*** -4.79*** 
Gender: Female vs. Male 0.36*** 0.76*** -1.76*** 
Medicaid Area 02 vs. 0121 1.33*** 0.79** - 0.59 
Medicaid Area 03 vs. 01 1.03 0.86   1.87 
Medicaid Area 04 vs. 01 1.20*** 0.61***   0.57 
Medicaid Area 05 vs. 01 1.02 0.90   2.72    * 
Medicaid Area 06 vs. 01 0.79*** 0.85    *   6.56*** 
Medicaid Area 07 vs. 01 1.31*** 0.71***   0.01 
Medicaid Area 08 vs. 01 0.73*** 0.89   7.62*** 
Medicaid Area 09 vs. 01 0.56*** 0.70***   0.99 
Medicaid Area 10 vs. 01 0.73*** 0.46***   0.57 
Medicaid Area 11 vs. 01 1.46*** 0.32*** -3.88*** 
Physician's Care Plan vs. MediPass 0.78*** 0.55***   7.09*** 
Wellcare Inc. vs. MediPass 0.90*** 0.73***   8.76*** 
Healthease vs. MediPass 0.73*** 0.63***   0.47 
PCA Family Health vs. MediPass 0.83*** 0.81***   5.34** 
Other HMOs Areas 10&11 vs. MediPass 0.68*** 0.33*** -4.91*** 
Other HMOs Areas 1-9 vs. MediPass 0.72*** 0.54*** -2.46* 
 
 
                                                 
20 ***  p<.001, ** p<.01, * p<.05 
21 Selection of Area 1 as the comparison Area was arbitrary.  Overall area effect was significant in all regression 
equations. 
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